| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Zevra Therapeutics, Inc.'s insiders have reduced their positions by a net 74,966 shares worth roughly $838K. In the past 30 days, 0 insiders bought and 1 sold.
The insider who sold still holds shares after the sale.
Counted by filing, the last 12 months brought no open-market purchases and 13 sales by 6 insiders worth about $2.5M. The 12 months before that brought 5 open-market purchases by 4 insiders worth about $310K and 6 sales by 5 insiders worth about $1.4M.
12 of the 13 sales in the last 12 months were made under a Rule 10b5-1 trading plan; the rest were not.
The largest open-market purchase in the last two years was 20,000 shares by Alvin Shih (Director) at an average $7.89 on September 12, 2025, about $158K. Twelve months later ZVRA was up 55%.
The most recent purchase was by Tamara A Favorito (Director) on September 12, 2025.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 417.2K | $4.28M | -20,000 | |
| CFO | 143.5K | $1.47M | - | |
| Dir | 123.4K | $1.27M | - | |
| Other | 62.3K | $639.0K | - | |
| Other | 37.6K | $385.5K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 12, 2026 | Neil F. McFarlane | President and CEO | Sale+OE10b5-1 | 20,000 | $11.25 | $224,948.00 | -4.6% | - | - | |
| Aug 14, 2026 | Rahsaan Thompson | Chief Legal & Compliance | Sell10b5-1 | 42,666 | $11.13 | $474,774.45 | -53.2% | - | - | |
| Aug 10, 2026 | Corey Michael Watton46 | Director | Sale+OE | 12,300 | $11.25 | $138,377.46 | -87.2% | - | - | |
| Jun 22, 2026 | Rahsaan Thompson | Chief Legal & Compliance | Sale+OE10b5-1 | 34,557 | $12.68 | $438,303.71 | -30.1% | -7.7% | - | |
| May 11, 2026 | Rahsaan Thompson | Chief Legal & Compliance | Sell10b5-1 | 1,794 | $11.30 | $20,272.20 | -3.6% | +6.3% | - | |
| Feb 9, 2026 | Neil F. McFarlane | President and CEO | Sale+OE10b5-1 | 14,625 | $8.56 | $125,185.61 | -3.6% | +26.0% | - | |
| Feb 3, 2026 | Joshua Schafer53 | CCO | Sell10b5-1 | 10,500 | $9.19 | $96,500.25 | -14.4% | +9.7% | - | |
| Feb 3, 2026 | Timothy J. Sangiovanni49 | SVP, Finance & Corp Controller | Sell10b5-1 | 3,000 | $9.18 | $27,548.10 | -9.2% | +9.7% | - | |
| Feb 2, 2026 | Neil F. McFarlane | President and CEO | Sale+OE10b5-1 | 91,000 | $9.38 | $853,425.30 | -20.0% | +7.4% | - | |
| Jan 30, 2026 | Timothy J. Sangiovanni49 | SVP, Finance & Corp Controller | Sale+OE10b5-1 | 1,750 | $8.82 | $15,442.00 | -7.7% | +13.0% | - |